Lv22
190 积分 2025-04-13 加入
Antibody–Drug Conjugates in SCLC: DLL3, B7-H3, TROP2, and Beyond
4天前
已关闭
Antibody–Drug Conjugates in SCLC: DLL3, B7-H3, TROP2, and Beyond
5天前
已关闭
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
1个月前
已完结
Sevabertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer
7个月前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
7个月前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
7个月前
已完结
Osimertinib combined with anlotinib as first-line treatment in advanced or metastatic NSCLC patients with EGFR mutation: a prospective, single arm, exploratory study
9个月前
已完结
Osimertinib combined with anlotinib as first-line treatment in advanced or metastatic NSCLC patients with EGFR mutation: a prospective, single arm, exploratory study
9个月前
已完结
Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial
9个月前
已完结
皖公网安备34019202002308
